Novel HER3 neutralizing antibody, patritumab abrogates cetuximab resistance mediated by a heregulin-autocrine loop in colorectal cancer

被引：0
|
作者：
Kawakami, Hisato [1 ]
Okamoto, Isamu [2 ]
Yonesaka, Kimio [3 ]
Okamoto, Kunio [1 ]
Kuwata, Kiyoko [1 ]
Morita, Yume [1 ]
Yamaguchi, Haruka [1 ]
Nishio, Kazuto [1 ]
Nakagawa, Kazuhiko [1 ]
机构：
[1] Kinki Univ, Fac Med, Osaka, Japan
[2] Kyushu Univ Hosp, Fukuoka 812, Japan
[3] Izumi Municipal Hosp, Osaka, Japan
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-1844
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1844
引用
收藏
页数：2
相关论文
共 42 条
  • [1] The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
    Kawakami, Hisato
    Okamoto, Isamu
    Yonesaka, Kimio
    Okamoto, Kunio
    Shibata, Kiyoko
    Shinkai, Yume
    Sakamoto, Haruka
    Kitano, Michiko
    Tamura, Takao
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    ONCOTARGET, 2014, 5 (23) : 11847 - 11856
  • [2] The expression level of HER3 ligand heregulin in mRNA as a predictive biomarker for anti-HER3 antibody patritumab combined with erlotinib in non-small cell lung cancer.
    Yonesaka, Kimio
    Kawakami, Hisato
    Kaneda, Hiroyasu
    Okamoto, Isamu
    Hirotani, Kenji
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
    Hussein Al-Akhrass
    James R. W. Conway
    Annemarie Svane Aavild Poulsen
    Ilkka Paatero
    Jasmin Kaivola
    Artur Padzik
    Olav M. Andersen
    Johanna Ivaska
    Oncogene, 2021, 40 : 1300 - 1317
  • [4] ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
    Ebbing, Eva A.
    Medema, Jan Paul
    Damhofer, Helene
    Meijer, Sybren L.
    Krishnadath, Kausilia K.
    Henegouwen, Mark I. van Berge
    Bijlsma, Maarten F.
    van Laarhoven, Hanneke W. M.
    ONCOTARGET, 2016, 7 (09) : 10243 - 10254
  • [5] A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance
    Al-Akhrass, Hussein
    Conway, James R. W.
    Poulsen, Annemarie Svane Aavild
    Paatero, Ilkka
    Kaivola, Jasmin
    Padzik, Artur
    Andersen, Olav M.
    Ivaska, Johanna
    ONCOGENE, 2021, 40 (07) : 1300 - 1317
  • [6] Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer
    Poovassery, Jayakumar S.
    Kang, Jeffrey C.
    Kim, Dongyoung
    Ober, Raimund J.
    Ward, E. Sally
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (02) : 267 - 277
  • [7] Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
    Koyama, Kumiko
    Ishikawa, Hirokazu
    Abe, Manabu
    Shiose, Yoshinobu
    Ueno, Suguru
    Qiu, Yang
    Nakamaru, Kenji
    Murakami, Masato
    PLOS ONE, 2022, 17 (05):
  • [8] Acquired resistance to cetuximab is mediated by HER3 activation in head and neck squamous cell carcinoma
    Yang, Yeon Ju
    Cho, Min Hee
    Oh, Yoo Jung
    Kim, Da Hee
    Kim, Jung Min
    Byeon, Hyung Kwon
    Ban, Myung Jin
    Kim, Ji Hoon
    Kim, Jae Wook
    Ku, Min Hee
    Yang, Jae Moon
    Choi, Eun Chang
    Koh, Yoon Woo
    Lee, Jeong Yeon
    CANCER RESEARCH, 2017, 77
  • [9] HEREGULIN AS A BIOMARKER FOR ANTI-HER3 ANTIBODY PATRITUMAB COMBINED WITH ERLOTINIB IN NON-SMALL CELL LUNG CANCER
    Yonesaka, Kimio
    Kawakami, Hisato
    Kaneda, Hiroyasu
    Okamoto, Isamu
    Hirotani, Kenji
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Soluble heregulin, HER3 ligand, to predict the efficacy of anti-HER3 antibody patritumab combination with erlotinib in randomized phase II study, HERALD, for non-small cell lung cancer.
    Yonesaka, Kimio
    Hirotani, Kenji
    Von Pawel, Joachim
    Dediu, Mircea
    Chen, Shuquan
    Copigneaux, Catherine
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345